DEF: Humacyte Seeks Stockholder Approval for Increased Share Authorization at 2025 Annual Meeting

Humacyte is asking stockholders to approve an amendment to its corporate charter to increase the number of authorized common shares from 250 million to 350 million at the upcoming annual meeting.

Summary

• Humacyte, Inc. will hold its Annual Meeting of Stockholders on June 10, 2025, virtually.
• Stockholders of record as of April 24, 2025, are entitled to vote.
• The meeting will address the election of four Class I directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm, and approval of an amendment to increase authorized common stock from 250,000,000 to 350,000,000 shares.
• The board recommends voting for all proposals.
• The company is providing proxy materials online to reduce environmental impact and costs.
• The company had 155,118,816 shares of common stock outstanding as of the record date.
• The board has fixed the current number of directors at 12.
• The company is soliciting proxies for the annual meeting.
• The company's proxy materials and annual report are available online.
• The company has a Code of Conduct and Ethics that applies to all officers, directors and employees.
• The company has an Audit Committee, a Nominating and Governance Committee, a Compensation Committee, and a Commercial Committee.
• The company has a Related Person Transactions Policy.
• The company has an insider trading policy that sets forth the policies and procedures with respect to trading in our securities to promote compliance with insider trading laws, rules and regulations, as well as the Nasdaq listing standards.
• The company has a CEO succession plan.
• The company has an annual cash bonus program for all employees.
• The company has a 401(k) retirement savings plan for its employees.
• The company has an Employee Stock Purchase Plan (ESPP).

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, so the sentiment is neutral to slightly positive. The company is taking steps to ensure good corporate governance and flexibility for future growth.

Positives

• The virtual format of the Annual Meeting aims to increase stockholder participation.
• Providing proxy materials online reduces environmental impact and costs.
• The board is actively engaged in risk oversight and strategic guidance.
• The company has a CEO succession plan in place.
• The company has a diverse board of directors.
• The company has a thoughtful board evaluation process.
• The company has a director onboarding process.
• The company has a Code of Conduct and Ethics that applies to all officers, directors and employees.
• The company has an insider trading policy that sets forth the policies and procedures with respect to trading in our securities to promote compliance with insider trading laws, rules and regulations, as well as the Nasdaq listing standards.
• The company has an annual cash bonus program for all employees.
• The company has a 401(k) retirement savings plan for its employees.
• The company has an Employee Stock Purchase Plan (ESPP).

Negatives

• Future issuances of common stock could dilute the earnings per share and voting power of existing stockholders.
• The availability for issuance of additional shares of common stock could enable the Board to render more difficult or discourage an attempt to obtain control of the Company.

Risks

• The company operates in a highly technical, regulated and competitive industry.
• The company's success depends on its ability to commercialize its product candidates.
• The company's success depends on its ability to maintain financial stability.
• The company's success depends on its ability to manage and expand capital.
• The company's success depends on its ability to enhance access to lending.
• The company's success depends on its ability to obtain grant funding to support pipeline activities.
• The company's success depends on its ability to ensure company-wide commitment to employee satisfaction and our inclusive culture.
• The company's success depends on its ability to ensure employee engagement and retention.

Future Outlook

The Authorized Share Amendment would provide us with the ability to issue common stock for a variety of corporate purposes if we so choose. These could include issuances in connection with equity incentive plans for our employees, to raise cash to expand our business, including through offerings of common stock or securities that are convertible into common stock, and for mergers and acquisitions activity, or other strategic transactions.

Industry Context

This announcement is typical for publicly traded companies as they prepare for their annual meetings and seek to maintain corporate flexibility.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, appears to be in line with industry standards for similarly sized biotech companies.
• The use of a virtual annual meeting format is becoming increasingly common, especially among companies seeking to reduce costs and increase accessibility for stockholders.
• The proposal to increase the authorized number of shares is a common practice, allowing the company flexibility for future financing and strategic opportunities.
• The company's corporate governance practices, such as having independent directors and key committees, align with Nasdaq listing requirements and best practices.

Related Party Transactions

• Humacyte has entered into customary indemnification agreements with the directors and executive officers of Humacyte following the Merger.
• In May 2022 and June 2023, we entered into three services agreements with Frenova Renal Research (Frenova), a subsidiary of Fresenius Medical Care, to conduct a study to review the outcomes of 178,575 adult patients who received in-center dialysis at Fresenius Kidney Care dialysis centers.
• In June 2024, we entered into a master services agreement with Frenova that sets forth the terms by which we may engage Frenova to provide certain services for projects, with the services for each project being described in a separate statement of work.
• In July 2024, we entered into a service agreement with Fresenius Medical Care Deutschland GmbH (Fresenius GmbH), which provides medical scientific research services through Frenova.
• In June 2018, Legacy Humacyte entered into a distribution agreement with Fresenius Medical Care, pursuant to which Fresenius Medical Care has the exclusive right to develop outside of the United States and EU and commercialize outside of the United States, among other things, our 6 millimeter x 42 centimeter ATEV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter, or configuration of the foregoing), referred to as the distribution product, for use in in vascular creation, repair and, replacement or construction (including renal replacement therapy for dialysis access, the treatment of vascular trauma, and the treatment of PAD, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients).
• Legacy Humacyte entered into three license agreements with Yale University, two of which currently remain in effect, and has made payments of license fees and other expenses to Yale, as described further in our Annual Report.

Stakeholder Impact

• Approval of the increased share authorization could provide the company with greater financial flexibility, potentially benefiting shareholders in the long term.
• The election of directors will shape the company's leadership and strategic direction.
• The ratification of the independent accounting firm ensures the integrity of the company's financial reporting.
• The company's commitment to corporate governance and ethical conduct benefits all stakeholders.
• The company's executive compensation policies are designed to align management's interests with those of shareholders.
• The company's employee benefit plans, such as the 401(k) and ESPP, support employee financial well-being.

Next Steps

• Stockholders need to review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting on June 10, 2025.
• The company will file a Current Report on Form 8-K with the SEC no later than the fourth business day after the Annual Meeting to report the final voting results.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, PricewaterhouseCoopers, authorized shares, common stock, corporate governance, executive compensation, audit committee, risk oversight, Humacyte